Not yet recruiting
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT07703436
- Conditions
- Astrocytoma IDH Mutant Grade 2, Astrocytoma IDH Mutant Grade 3, Glioma, +12 more
- Locations
-
- University of California, Los Angeles Los Angeles, California, United States
- University of California, San Francisco San Francisco, California, United States
- Rutgers Cancer Institute New Brunswick, New Jersey, United States
- NYU Langone Health New York, United States